er positive her2 breast cancer epidemiology forecast

DelveInsight's ‘ER+/HER2− Breast Cancer - Epidemiology Forecast–2034’ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Geography Covered

The United States
EU4 (Germany, France, Italy, and Spain), and the United Kingdom
Japan

Study Period: 2021-2034

ER+/HER2− Breast Cancer Disease Understanding

ER+/HER2− Breast Cancer Overview

Breast Cancer initiates when abnormal cancerous cells in the breast grow and multiply without stopping, creating a tumor. It usually starts in the ducts or lobules of the breast. Cancer cells get many signals that drive their growth. These signals may take the form of hormones.

Hormone receptors are proteins that receive hormone signals and tell the cancer cells to grow. If Breast Cancer cells get signals from the hormone estrogen that could promote tumor growth, it is known as estrogen receptor-positive (ER+) Breast Cancer. If cancerous cells get signals from the hormone progesterone that could promote growth, it is known as progesterone receptor-positive (PR+) Breast Cancer. Breast Cancer that is ER+ or PR+ falls under the category of hormone receptor-positive (HR+) Breast Cancer.

Additionally, there is another category of Breast Cancer, which is known as hormone receptor-negative (HR−). This type of Breast Cancer has cells without hormone receptors. HR- Breast Cancer cells do not depend on estrogen or progesterone to grow.

Addition to this, there is another factor, which is also responsible for Breast Cancer, which is known as human epidermal growth factor receptor 2 (HER2). Human epidermal growth factor receptor-2 is a gene that helps control how cells grow, divide, and repair themselves. These proteins are receptors on breast cells. Human epidermal growth factor receptor-2 positive (HER2+) is Breast Cancer that tests positive for the HER2 protein. HER2+ Breast Cancer tends to grow faster and is more likely to spread and come back compared to human epidermal growth factor receptor-2 negative (HER2−) Breast Cancer. Patients HER2 status is determined by whether Breast Cancer tests are positive or negative for the HER2 protein.

In HER2−negative, cancer cells do not have high amount of a protein called HER2 on their surface. Cancer cells that are HER2 negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface.

ER+/HER2− Breast Cancer Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total incident population of Breast Cancer, incidence of Breast Cancer cases by menopausal status, stage-specific incidence of Breast Cancer, subtype-specific incidence of Breast Cancer, and treatment eligible pool for localized and metastatic Breast Cancer in the 7MM market covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2021 to 2034.

Key Findings

This section provides glimpse of the ER+/HER2− Breast Cancer epidemiology in the 7MM

Country Wise- ER+/HER2− Breast Cancer Epidemiology

The epidemiology segment also provides the ER+/HER2− Breast Cancer epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan

The total incident population of Breast Cancer in the United States is 256,431 in 2021
In the United States, more cases were observed for postmenopausal Breast Cancer, with 205,145 cases in 2021
In 2021, cases of localized, regional, distant and unknown stage were observed to be 164,116, 74,365, 15,386 and 2,564 respectively. This number might increase during forecast period
Among the various subtypes of the disease (localized and regional), ER+/HER2− occupies the maximum patient pool, with 147,977 cases of this category, followed by the number of those with 24,325 cases of Triple-negative and 20,271 cases of ER+/HER2+. On the other hand, HR−/HER2+ accommodated the least number of cases

Scope of the Report

The report covers the descriptive overview of ER+/HER2− Breast Cancer, explaining its causes, signs and symptoms, pathogenesis and diagnosis
Comprehensive insight has been provided into the ER+/HER2− Breast Cancer Treatment
The report provides insight about the historical and forecasted patient pool of ER+/HER2− Breast Cancer in seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
A detailed review of ER+/HER2− Breast Cancer epidemiology forecast is included in the report, covering the 7MM drug outreach
The report provides an edge while developing business strategies, by understanding epidemiological trends

Report Highlights

In the coming years, ER+/HER2- Breast Cancer Market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, increase in incidence population
As per DelveInsight’s analysis, the major types of Breast Cancer include invasive, non-invasive, ductal carcinoma, lobular carcinoma, and others
The report also encompasses other major segments, i.e., total incident population of Breast Cancer, incidence of Breast Cancer cases by menopausal status, stage-specific incidence of Breast Cancer, subtype-specific incidence of Breast Cancer, and treatment eligible pool for localized and metastatic Breast Cancer

ER+/HER2- Breast Cancer Report Insights

Patient Population
Eleven Years Forecast
7MM Coverage
ER+/HER2- Breast Cancer Epidemiology Segmentation

Key Questions

What is the disease risk, burden and unmet needs of ER+/HER2- Breast Cancer?
What is the historical ER+/HER2- Breast Cancer patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
What would be the forecasted patient pool of ER+/HER2- Breast Cancer at the 7MM level?
What will be the growth opportunities across the 7MM with respect to the patient population pertaining to ER+/HER2- Breast Cancer?
Out of the above-mentioned countries, which country would have the highest incident population of ER+/HER2- Breast Cancer during the study period (2021-2034)?
At what CAGR the population is expected to grow across the 7MM during the study period (2021-2034)?

Reasons to buy

The report will help in developing business strategies by understanding trends shaping and driving the ER+/HER2- Breast Cancer
To understand the future market competition in the ER+/HER2- Breast Cancer market and Insightful review of the unmet needs.
Quantify patient populations in the global ER+/HER2- Breast Cancer market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the best opportunities for ER+/HER2- Breast Cancer in the US, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
The ER+/HER2- Breast Cancer epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources.

Stay Updated with us for Recent Articles:-